THE MAIN OBJECTIVE OF THIS DEPARTMENT IS TO:
Adopt and contribute to an emerging medical discipline called “Genomic Medicine”.
Implement genetic testing as the standard of care for treating cancer at an affordable cost for all patients through the use of genomic data from patients for better diagnosis, effective therapeutic decisions, and overall improved health outcomes.
Help patients achieve longer and better lives and improve outcomes.
An in-depth understanding of the genetic profile of cancer cells will enable us to adopt innovative diagnostic and treatment protocols, contribute to an emerging medical discipline called “Genomic Medicine”, and develop novel therapeutic drugs and technologies to offer individualized treatment for each cancer case, as every patient is different. The robust database generated from this project will help us find new genetic alterations in cancer cells and correlate these alterations to the therapeutic response. This approach will eventually help the clinicians stratify the patients into responders and non-responders effectively and offer them the “right treatment at the first time.”
With a high disease burden, a large patient base at the hospital, seamless availability of a well-annotated tissue biorepository, fully maintained clinical data, and the strong clinical excellence of the oncologists and scientists at “The Center of Cancer Genomics”, we are best placed to study the genomic profiling data of tumor samples and provide robust analysis and biological interpretation of the large data using an analytics and interpretation platform. By doing this, Triesta Sciences takes leadership in cancer genetics and develops a “Genomic Bank” with complete clinical and genomic data.